BUZZ - Broker perspectives: Schneider - The rationale for PTC trading is "clear," but AI, integration, and financing pressures are imminent
路透社2026/10/05 10:41October 5th - Schneider Electric (SCHN.PA) will acquire US software company PTC (PTC.O) for $22.6 billions, marking the company’s largest deal ever and signifying its further commitment to the industrial artificial intelligence sector. The announcement of the deal, which includes raising substantial equity and debt financing, led to a roughly 9% drop in Schneider’s share price; however, analysts generally recognized the logic behind this move amid AI anxieties and execution risks. Jefferies analysts noted there is a “very clear” strategic rationale, as it fills one of the remaining gaps in Schneider’s software portfolio. JPMorgan pointed out that this “complementary” fit should also help ease antitrust scrutiny. Baird added that, among all bidders, Schneider Electric’s industrial rationale is the strongest. However, both Jefferies and RBC highlighted the industry’s concerns about disruption from artificial intelligence—concerns that allowed Schneider to acquire PTC at its lowest valuation in a decade—which could potentially affect the French company’s share price post-deal. RBC added that the significant debt needed to finance the transaction may reignite worries over Schneider’s longstanding spending issues. JPMorgan noted the complexity of the integration process, pointing out that large-scale M&A typically receives a lukewarm response in Europe, “even though Schneider Electric’s deals have generally proven to be strategically farsighted.” (For readers who are not native English speakers, Reuters has provided automated translation of its reports in several languages for convenience. As automated translation may contain errors or fail to convey full context, Reuters does not guarantee the accuracy of such automated texts and accepts no responsibility for any damages or losses resulting from their use.)
October 5 - ** Schneider Electric (SCHN.PA) will acquire US software company PTC (PTC.O) for $22.6 billion (link), marking the company's largest transaction ever and signaling its increased commitment to the industrial artificial intelligence sector.
** News of the deal (including the need to raise large amounts of equity and debt) caused Schneider’s share price to drop by about 9%, but analysts generally recognize the logic behind the acquisition.
AI Anxiety and Execution Risk
** Analysts at Jefferies believe the deal has a “very clear” strategic rationale, as it fills one of the remaining gaps in Schneider’s software portfolio; J.P. Morgan notes that this “complementary” fit should also help alleviate antitrust scrutiny.
** Baird adds that, among all the bidders, Schneider Electric’s industrial rationale is the most compelling.
** However, both Jefferies and Royal Bank of Canada point out worries in the industry about AI disruption—these anxieties made it possible for Schneider to acquire PTC at its lowest valuation in a decade—which could impact the French company’s share price after the deal is completed.
** Royal Bank of Canada adds that the large amount of debt needed to finance the transaction might rekindle market concerns about Schneider’s longstanding spending issues.
** J.P. Morgan highlights the complexity of the integration process, also noting that major acquisitions in Europe are often met with lukewarm reactions, “even though Schneider Electric’s deals typically prove to be strategically farsighted.”
(To facilitate non-English speakers, Reuters automatically translates its reports into several other languages. Because automated translation may contain errors or lack needed context, Reuters does not guarantee the accuracy of automated translation and provides it solely to assist readers. Reuters accepts no liability for any damage or loss caused by the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley Analyst Says SpaceX Stock Price Could Double
Getlink reports 550,000,000 shares outstanding, 642,851,718 total voting rights as of Sept. 30, 2026
Getlink disclosed 550,000,000 ordinary shares outstanding as of Sept. 30, 2026. Theoretical voting rights totaled 642,851,718. Exercisable voting rights stood at 635,332,063. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Getlink SE published the original content used to generate this news brief via Business Wire (Ref. ID: 202610051200BIZWIRE_USPR_____20261005_BW048564) on October 05, 2026, and is solely responsible for the information contained therein.
European Equities Traded in the US as American Depositary Receipts Track Lower in Monday Trading
11:12 AM EDT, 10/05/2026 (MT Newswires) -- European equities traded in the US as American depositary receipts opened the week lower late Monday morning, declining 0.14% to 1,883.96 on the S&P Europe Select ADR Index. From continental Europe, the gainers were led by lender Banco Santander (SAN) and brewing company Anheuser-Busch InBev (BUD), which advanced 3.2% and 0.8% respectively. They were followed by 3D printer company Materialise (MTLS) and internet browser company Opera (OPRA), which were up 0.6% and 0.3% respectively. The decliners from continental Europe were led by biopharmaceutical company Nokia (NOK) and biopharmaceutical company Cellectis (CLLS), which lost 3.2% each. They were followed by biopharmaceutical company DBV Technologies (DBVT) and petroleum refiner Equinor (EQNR), which decreased 0.9% and 0.4%, respectively. The gainers from the UK were led by biopharmaceutical company Bicycle Therapeutics (BCYC) and software firm Endava plc (DAVA), which climbed 17% and 1.6% respectively. They were followed by medical device maker Smith & Nephew (SNN) and biotech firm Trinity Biotech (TRIB), which increased 1.2% and 1.4% respectively. The decliners from the UK and Ireland were led by pharmaceutical company Silence Therapeutics (SLN) and biopharmaceutical company Biodexa Pharmaceuticals (BDRX), which dropped 3.9% and 1.4% respectively. They were followed by hospitality company InterContinental Hotels Group (IHG) and pharmaceutical company GSK (GSK), which fell 1.1% and 1% respectively.
Bitcoin Returns Reliant on Major Days -- Market Talk
1105 ET - Bitcoin's strong year-over-year returns are more linked to single days of strong moves, according to Zach Pandl of Grayscale in a note. Pandl says removing bitcoin's five best trading days reduces its three-year return from 225% to 95%, with the return falling to 27% without its 10 best days. If you remove the top fifteen days, it turns a three-year gain into an 11% loss. By comparison, removing the Nasdaq's fifteen best days reduces its cumulative return from 109% to 21%. "Given BTC's return and volatility profile, investors looking for long-term capital appreciation can avoid trying to time the market and instead seek consistent, long-term exposure to the asset," Pandl says. Bitcoin is down 0.2% to $85,610, while ethereum falls 0.2% to $2,701. (kirk.maltais@wsj.com) (END) Dow Jones Newswires October 05, 2026 11:05 ET (15:05 GMT)
Crypto prices
More
